Skip to main content

Cumberland Pharmaceuticals Inc.

corporate_fare Company Profile

Cumberland Pharmaceuticals Inc.

CPIX·NASDAQ·Life Sciences·CIK 0001087294

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company that acquires, develops, and sells branded prescription pharmaceuticals. The company focuses on hospital acute care, gastroenterology, and oncology markets. Cumberland promotes its approved products in the United States through its hospital, field, and oncology sales divisions. It also works with international partners to register and provide its medicines to patients in other countries. Cumberland's portfolio of brands approved by the U.S. Food and Drug Administration (FDA) includes: * **Acetadote® (acetylcysteine) injection:** Used to treat acetaminophen poisoning. * **Caldolor® (ibuprofen) injection:** Used to treat pain and fever. * **Kristalose® (lactulose) oral solution:** A prescription laxative for constipation. * **Sancuso® (granisetron) transdermal:** Prevents nausea and vomiting in patients undergoing certain chemotherapy treatments. * **Vaprisol® (conivaptan) injection:** Raises serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia. * **Vibativ® (telavancin) injection:** Treats certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, and complicated skin and skin structure infections. * **Tacilia® (omeprazole, amoxicillin, and rifabutin) oral capsule:** Treats H. pylori infection. The company has also reported results from a clinical study of its ifetroban product candidate for cardiomyopathy associated with Duchenne muscular dystrophy (DMD).

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 25 items for CPIX at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Cumberland Pharma to Integrate Commercial Business with Apotex in Strategic Transaction
  • Cumberland Pharmaceuticals Sells Commercial Business to Apotex for $100M, Pivots to Orphan Drug Pipeline
  • Cumberland Pharmaceuticals Reports Strong 2025 Growth, Advances Key Pipeline Drugs, and Secures Capital
  • Cumberland Pharmaceuticals Reports Strong 2025 Revenue Growth, Positive Cash Flow, and Key Strategic Milestones
  • FDA Grants Fast Track Designation for Cumberland Pharma's DMD Heart Disease Therapy

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$44.52M
Net Income
-$2.84M
Diluted EPS
-$0.19
Op. Cash Flow
$4.93M
Free Cash Flow
$4.83M
Gross Profit
$37.85M
Operating Income
-$2.79M
Cash & Equivalents
$11.44M
Total Debt
$0
Debt / Equity
0.00×
Net Margin
-6.4%
Shares Outstanding
14.96M sh
Source: 10-K · filed 2026-03-07 · accession 0001087294-26-000020
$5.74 -1.70% today
52-week range · as of 2026-11-13 $1.85 – $9.28
Market cap
$87.57M
Volume
124.6K (0.7× avg)
3-mo avg 188.8K
Live data · 2026-11-21 18:26 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CPIX - Filings & News (Page 2)

CPIX
Apr 23, 2026, 9:02 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $4.45
Real-time Price: $5.74 info
Change: +$1.29 (+29%) info
Market Cap: $87.574M info
CPIX
Apr 23, 2026, 9:01 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $5.04
Real-time Price: $5.74 info
Change: +$0.7008 (+14%) info
Market Cap: $87.574M info
CPIX
Mar 06, 2026, 8:54 PM EST
Filing Type: 10-K
Importance Score:
9
Price at Filing: $3.50
Real-time Price: $5.74 info
Change: +$2.24 (+64%) info
Market Cap: $87.574M info
CPIX
Mar 03, 2026, 5:10 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.64
Real-time Price: $5.74 info
Change: +$1.10 (+24%) info
Market Cap: $87.574M info
CPIX
Feb 04, 2026, 5:20 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.94
Real-time Price: $5.74 info
Change: +$1.80 (+46%) info
Market Cap: $87.574M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets